Insider Buying: Zai Lab (NASDAQ:ZLAB) Director Buys $33,389.32 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) Director Richard Gaynor bought 1,228 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The shares were purchased at an average cost of $27.19 per share, for a total transaction of $33,389.32. Following the acquisition, the director directly owned 81,965 shares in the company, valued at $2,228,628.35. This trade represents a 1.52% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Zai Lab Price Performance

NASDAQ ZLAB opened at $24.60 on Monday. The company’s 50 day simple moving average is $24.62 and its two-hundred day simple moving average is $21.26. Zai Lab Limited Unsponsored ADR has a 1 year low of $15.96 and a 1 year high of $29.02. The stock has a market capitalization of $3.08 billion, a PE ratio of -13.74 and a beta of 0.77.

Zai Lab (NASDAQ:ZLAB – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. The firm had revenue of $108.21 million during the quarter, compared to analyst estimates of $107.90 million. Zai Lab had a negative net margin of 44.91% and a negative return on equity of 31.15%. On average, research analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.19 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ZLAB shares. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research note on Tuesday, October 6th. Wall Street Zen upgraded Zai Lab from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. Finally, Citigroup boosted their price objective on Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

Read Our Latest Report on ZLAB

Institutional Trading of Zai Lab

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Nantahala Capital Management LLC raised its position in shares of Zai Lab by 65.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 330,000 shares of the company’s stock worth $8,692,000 after acquiring an additional 130,000 shares in the last quarter. HighVista Strategies LLC purchased a new position in shares of Zai Lab in the 3rd quarter valued at approximately $609,000. Nan Fung Trinity HK Ltd. boosted its position in shares of Zai Lab by 106.9% during the third quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock valued at $7,743,000 after purchasing an additional 151,883 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Zai Lab by 34.9% during the third quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock valued at $3,924,000 after purchasing an additional 38,562 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zai Lab during the third quarter valued at approximately $62,000. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Zai Lab News Roundup

These are some of the ZLAB news items that stood out recently:

About Zai Lab

(Get Free Report)

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.

Recommended Stories

Insider Buying and Selling by Quarter for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.